Ensysce Biosciences, Inc. (ENSC) Stock

Ensysce Biosciences, Inc. is a dynamic clinical-stage pharmaceutical company dedicated to advancing prescription drugs tailored for managing severe pain while addressing challenges related to opioid addiction, misuse, abuse, and overdose in the United States. The company specializes in innovative prodrug technologies including the Trypsin Activated Abuse Protection (TAAP) platform and the Multi-Pill Abuse Resistance (MPAR) platform.

Central to its portfolio is PF614, an oxycodone prodrug currently in Phase II clinical trials for treating both acute and chronic pain. Ensysce Biosciences is also developing PF614-MPAR, a combination product of PF614 with nafamostat, aimed at providing overdose protection against excessive oral ingestion, and exploring its potential for treating coronaviral infections and pulmonary diseases such as cystic fibrosis via oral and inhalation formulations of nafamostat.

Additionally, the company is advancing PF329, an extended-release prodrug of hydromorphone similar to PF614, along with PF8001 and PF8026, extended and immediate-release prodrugs of amphetamine designed to address abuse in ADHD medication. Ensysce Biosciences is also developing PF26810, an extended-release prodrug of methadone targeting opioid use disorder. Headquartered in La Jolla, California, Ensysce Biosciences continues to innovate in pain management and addiction treatment, leveraging cutting-edge science to enhance patient care and safety.